Castle Biosciences EBIT

As of the most recent data (June 2026), CSTL shows a EBIT of $-24M. That compares with $1.9M in the prior-year period — down 1392.3% year over year. That is below the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CSTL's EBIT is now $-24M (was $1.9M) — a 1392.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Castle Biosciences is outperforming or lagging.

The Healthcare sector average EBIT is about $22B. Castle Biosciences is at $-24M, which is lower that average. That is roughly 100.1% below the sector mean. Use the comparison chart on this page to see how CSTL stacks up against individual peers as well.

Tracking CSTL's ebit over time shows whether Castle Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $-24M That compares with $1.9M in the prior-year period — down 1392.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Castle Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-24M) with ownership activity and broader fundamentals.